CureVac aims to become one of Europe's big suppliers.
Compare CVAC Stock to Peers
|Symbol||Last Price||Market Cap||% Δ 1 Yr||% Δ 5 Yr|
News & Analysis: CureVac
Funds will not be safe if invested in this coronavirus stock.
CureVac shares have slipped more than 20% on bad news.
Investors' dreams of a third strong mRNA vaccine may be over.
Things are looking bleak right now, but they might improve with enough time.
CureVac's first COVID vaccine candidate disappointed investors. But a second one looks promising.
This coronavirus vaccine developer just hit a massive stumbling block.
The news may reinforce Moderna's and Pfizer's vaccine-market dominance.
The biotech's COVID-19 vaccine candidate no longer appears to be viable.
This biotech's coronavirus vaccine candidate could be the next to hit the market -- but a lot of its potential success has been priced in.